Barr Inks Second Settlement Over Its Delay In Launching Generic Ovcon
Executive Summary
Barr Pharmaceuticals has agreed to pay 34 states and the District of Columbia $5.9 million to settle an antitrust suit over Barr's delay in marketing a generic version of the oral contraceptive Ovcon 35